chemistry

Sparsentan

Sparsentan is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Sparsentan rather than just read about it. In short: Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy and focal segmental glomerulosclerosis. Sparsentan is an endothelin and angiotensin II receptor antagonist.

Key takeaways

Sparsentan belongs to chemistry; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Sparsentan to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Sparsentan from memory before moving on to harder problems.

Reference excerpt

Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy and focal segmental glomerulosclerosis. Sparsentan is an endothelin and angiotensin II receptor antagonist. It is taken by mouth. The most common side effects include swelling of the extremities, low blood pressure, dizziness, high blood potassium, anemia, injury to the kidney, and increased liver enzymes in the blood. It was approved for medical use in the United States in February 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. The drug was approved for the treatment of focal segmental glomerulosclerosis in April 2026.

Medical uses Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy.

Adverse effects The most common side effects include swelling of the extremities, low blood pressure, dizziness, high blood potassium, anemia, injury to the kidney, and increased liver enzymes in the blood. Other potential risks of sparsentan include low blood pressure, injury to the kidney, high potassium in the blood, and fluid retention. Sparsentan can cause changes in liver tests. Some medicines that are like sparsentan can cause liver failure. Sparsentan can cause serious birth defects if taken during pregnancy and should not be started in someone who is pregnant.

History Sparsentan was discovered by Pharmacopeia, Inc. and developed as PS433540 as their lead compound in a new class of agents called dual acting receptor antagonists (DARA). PS433540 was originally developed as a treatment for hypertension and diabetic nephropathy. After Pharmacopeia was acquired by Ligand Pharmaceuticals, the DARA programs was licensed to Retrophin and developed as RES-021 in 2012. Retrophin would then be rebranded as Travere Therapeutics. Sparsentan was evaluated in a randomized, double-blind, active-controlled, clinical trial (PROTECT) in participants with IgA nephropathy. Participants with IgA nephropathy and protein in the urine were randomly assigned to receive either sparsentan or irbesartan once daily. The primary endpoint for accelerated approval was the mean change in urine protein at week 36 compared to baseline. The US Food and Drug Administration (FDA) granted accelerated approved to sparsentan based on evidence from a clinical trial (PROTECT) of participants with IgA nephropathy. The trial was conducted at 156 sites in 18 countries in North America, Europe, and Asia-Pacific. The same trial was used to assess both efficacy and safety. The efficacy analyses were based on an interim analysis of 281 participants (141 on sparsentan, 140 on irbesartan) who reached week 36 in the trial. The safety analyses were based on 404 participants (202 each on sparsentan and irbesartan) who received at least one dose of either drug.

Society and culture

Legal status Sparsentan was approved in the US under accelerated approval based on reduction of proteinuria. In September 2024, the US FDA converted the conditional approval in the kidney disease IgA nephropathy (IgAN) into a full approval based on positive long-term confirmatory results from the PROTECT Study demonstrating that sparsentan significantly slowed kidney function decline over two years compared to irbesartan. In February 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a conditional marketing authorization for the medicinal product Filspari, intended for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). The applicant for this medicinal product is Vifor France. Sparsentan was approved for medical use in the European Union in April 2024.

References

External links Clinical trial number NCT03762850 for "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)" at ClinicalTrials.gov

Illustrations

Worked examples

Example 1 — a first encounter with Sparsentan

Start with the simplest possible case. Write down what Sparsentan claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Sparsentan before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Sparsentan ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Sparsentan

In research: Sparsentan appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Sparsentan in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Sparsentan is common in secondary-school and first-year university syllabi. It links to neighbouring topics Arylsulfonamides, Biphenyls, Cyclopentanes, so understanding it makes those chapters shorter.
In everyday life: Look for Sparsentan outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Sparsentan in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Sparsentan means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Sparsentan out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Sparsentan in simple terms?

Why does Sparsentan matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Sparsentan?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Sparsentan.